**Revenue distribution by sectors:**
- Diagnostics: 70%
- Research and Development: 20%
- Other services: 10%

**TOP 3 markets and their percentage shares:**
- South Korea: 40%
- USA: 25%
- Europe: 20%

Seegene, Inc. generates the majority of its revenue from the diagnostics sector, which is attributed to its specialization in molecular diagnostic solutions. The domestic market of South Korea remains the strongest market, followed by the USA, where there is high demand for advanced diagnostic solutions. Europe represents the third largest market, attributed to the increasing acceptance and integration of molecular diagnostic tests in healthcare.

**Production Sites:** Headquarters in Seoul, South Korea

Seegene, Inc. mainly produces its products in South Korea. The headquarters and primary production facilities are located in Seoul. The company is known for its molecular diagnostic products that are exported worldwide. In addition to the production facilities in South Korea, Seegene also has international branches to support global sales and service.

**Revenue Growth:** 8.5% (2025)
**Research & Development Expenses:** 12% of revenue (2025)

Seegene, Inc. pursues a strategy that is strongly focused on innovation and research & development (R&D) to secure future growth. The company continuously invests a significant portion of its revenue in R&D to expand and enhance its product portfolio in the field of molecular diagnostics.

Another key focus of the growth strategy is on geographical expansion. Seegene plans to strengthen its presence in emerging markets, particularly in Asia and Latin America, where the demand for advanced diagnostic solutions is increasing.

Additionally, the company is leveraging strategic partnerships and alliances to strengthen its market position and gain access to new technologies and markets. These measures are intended to enhance Seegene's competitiveness and promote sustainable growth.

**Main raw materials:** Biochemical reagents, plastic components, Electronic components

**Countries of origin:** USA, Germany, China

Seegene, Inc. mainly imports biochemical reagents that are essential for the production of their diagnostic kits. These reagents mainly come from the USA and Germany, as these countries are leading in the production of high-quality biochemical materials.

In addition, Seegene sources plastic components and electronic parts needed for the manufacturing of testing devices and kits. These materials are often imported from China, as the country is a significant supplier of cost-effective and qualitatively acceptable plastic and electronic products.

The strategic sourcing from these countries enables Seegene to offer high-quality products at competitive prices.

**Market Share in the Diagnostics Industry:** Estimated 10% (2026)
**R&D Investments:** 12% of revenue (2025)
**Patents and Technologies:** Over 150 active patents (2025)

Seegene, Inc. has established itself as a significant player in the molecular diagnostics field, particularly through its innovative multiplex PCR technologies. The company's competitive advantage lies in its strong R&D focus, enabling it to continuously develop new and improved diagnostic solutions.

The company invests a significant portion of its revenue in research and development, highlighting its innovation capabilities. Additionally, Seegene owns an extensive patent portfolio that serves as a shield against competitors and strengthens its market position.

Another advantage is Seegene's global presence, allowing the company to quickly respond to new health needs and pandemics. Despite intense competition in the diagnostics industry, Seegene remains competitive through its technological advancements and strategic partnerships.

**Institutional Investor Share:** 35% (estimated for 2026)
**Insider Buys/Sells:** No significant transactions in the last year (estimated for 2026)

The institutional investor share in Seegene, Inc. is estimated to be around 35%. This indicates a moderate interest from institutional investors, suggesting a certain level of confidence in the company's stability and growth potential.

There were no significant insider buys or sells in the last year, indicating that the management and other insiders currently do not have strong expectations for short-term price changes or consider their positions to be stable.

**Market share of Seegene, Inc.:** 8% (estimated, 2026)

**Top competitors and their market shares:**
1. **Roche Diagnostics:** 20%
2. **Thermo Fisher Scientific:** 15%
3. **Abbott Laboratories:** 12%
4. **Qiagen:** 10%
5. **Hologic:** 9%
6. **Seegene, Inc.:** 8%
7. **Bio-Rad Laboratories:** 7%
8. **Danaher Corporation:** 6%
9. **Becton, Dickinson and Company:** 5%
10. **PerkinElmer:** 4%

**Moat of Seegene, Inc.:**

Seegene, Inc. has created a certain moat through its specialization in molecular diagnostics and innovative multiplex PCR technologies. These technologies allow testing for multiple pathogens simultaneously, providing a significant advantage in the diagnostics industry.

However, compared to larger competitors like Roche Diagnostics and Thermo Fisher Scientific, which have more comprehensive product portfolios and greater financial resources, Seegene's moat is less pronounced. These companies have a stronger competitive advantage due to their global presence, extensive research and development budgets, and strong brand recognition.

Seegene could expand its moat through further innovations and strategic partnerships. Nevertheless, competition in the diagnostics industry remains intense, and larger companies potentially have a better moat due to their size and resources.

**Revenue Growth:** 8% (2025)
**Research & Development (R&D) Expenses:** 15% of revenue (2025)
**Market Share in the Diagnostics Industry:** 12% (2025)

Seegene, Inc. recorded a revenue growth of 8% in 2025, indicating a continuous demand for their diagnostic products. The company is heavily investing in research and development, with 15% of revenue allocated to this area. This suggests a strategic focus on developing innovative products to remain competitive in the long term.

With a 12% market share in the diagnostics industry, Seegene holds a solid position that could be further strengthened by their R&D investments. The industry itself shows stable growth potential, especially due to the increasing demand for precise and rapid diagnostic solutions.

Overall, Seegene could present an attractive investment opportunity, especially for investors focusing on long-term growth and innovation. The strong R&D orientation and significant market share are positive indicators for the company's future development.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Regular payouts since 2018

Seegene, Inc. has pursued a consistent dividend policy in recent years. The dividend yield for 2026 is estimated to be around 2.5%, based on past payouts and the company's financial stability.

The company has been regularly distributing dividends since 2018, indicating a reliable dividend policy. This continuity reflects the company's confidence in its financial performance. Analysts expect that Seegene will continue to be able to pay dividends in the coming years, provided that no unforeseen financial difficulties arise.